ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

doi:10.1038/s41408-021-00541-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

Blood cancer journal - 21 Sept 2021

Rahmani Nora E, Ramachandra Nandini, Sahu Srabani, Gitego Nadege, Lopez Andrea, Pradhan Kith, Bhagat Tushar D, Gordon-Mitchell Shanisha, Pena Bianca Rivera, Kazemi Mohammad, Rao Keshav, Giricz Orsi, Maqbool Shahina Bano, Olea Raul, Zhao Yongmei, Zhang Jinghang, Dolatshad Hamid, Tittrea Vickram, Tatwavedi Dharamveer, Singh Shalini, Lee Juseong, Sun Tianyu, Steidl Ulrich, Shastri Aditi, Inoue Daichi, Abdel-Wahab Omar, Pellagatti Andrea, Gavathiotis Evripidis, Boultwood Jacqueline, Verma Amit

Abstract excerpt

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Epigenesis, Genetic

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Point Mutation

Share to Repressor Proteins

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34548471
DOI: 10.1038/s41408-021-00541-0
PMCID: PMC8455571

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.PMID 34548471Read ↗

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemiaSemantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromesSemantic proximity Read ↗

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesSemantic proximity Read ↗

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous LeukemiaSemantic proximity Read ↗

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read ↗

MCL1 dependence across MDS subtypes and dual inhibition of MCL1 and BCL2 in MISTRG6 miceSemantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.